Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SensiCab: Cabazitaxel and Hormone Therapy in Prostate Cancer
NCT01978873Phase 3Unknown
- Sponsor
- Örebro University
- Start
- Nov 2012
- Primary completion
- Nov 2018
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 3 trial of cabazitaxel in prostate cancer (PCa), sponsored by Örebro University. Status: unknown.
02
Drugs
cabazitaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01978873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01978873.